TABLE 2

FROM:

Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial

F Donskov, M Hokland, N Marcussen, H H Torp Madsen and H von der Maase

Table 2. Baseline patient characteristics

	IL-2 plus Histamine Study Group N=30		IL-2 alone Control Group N=29
	N	%	N	%
Median age, years (range)	55	(31–69)	60	(36–69)
Male	24	80	16	55
Karnofsky performance status
100	16	53	12	41
90	10	33	13	45
80	2	7	2	7
70	2	7	2	7
Metastasis-free interval 1 year	22	73	20	69
Baseline blood neutrophils
Median ( 109 l-1), (range)	5.43	(2.61–15.91)	5.54	(2.01–10.33)
Baseline blood monocytes
Median ( 109 l-1), (range)	0.74	(0.35–1.51)	0.69	(0.32–1.11)
Baseline blood CD16+56+ NK-cells
Median ( 109 l-1), (range)	0.1	(0.02–0.36)	0.06	(0.01–0.39)
Prior therapy
Nephrectomy	17	57	18	62
Excision of metastatic lesions	3	10	1	3
Number of disease organ sites
1	2	7	3	10
2	7	23	7	24
3 or more	21	70	19	66
Most common sites of disease
Primary kidney tumour	13	43	12	41
Local recurrence kidney bed	4	13	5	17
Lung/pleura	23	77	22	76
Lung metastasis alone	1	3	0	0
Lymph node	21	70	17	59
Liver	3	10	7	24
Bone	11	37	10	35
Soft tissue	5	17	4	14
MSKCC prognostic criteria a
Favorable prognosis	6	20	5	17
Intermediate prognosis	20	63	18	62
Poor prognosis	4	13	6	21

^a Memorial Sloan–Kettering Cancer Center (Motzer et al, 1999).